Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COMPUGEN LTDCGEN · Entity 6149 | Chief Medical Officer | July 29, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COMPUGEN LTD
Report date July 29, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 36,625 |
Reported balance
After 2026-07-29 transaction · row 1
1 source rowRow 1 · 2026-07-29 · Grant · Acquired 13,500 · Balance 36,625 F1: Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.26 · Expires 2036-07-29 | Direct | 18,000 |
Reported balance
After 2026-07-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-29 · Grant · Acquired 18,000 · Balance 18,000 F2: This option vests 25% on September 30, 2027 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
F2: This option vests 25% on September 30, 2027 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2026 Filed Jul 30, 2026 20:01 UTC | COMPUGEN LTD CGEN · Entity 6149 | GrantShare Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001178913-26-003706 · zk2635765.xml · derivative · entry 2 Mahler Michelle · CIK 0002041318 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Ordinary Shares · 18,000 shares Expires 2036-07-29 F2 · derivative.exercise_date: This option vests 25% on September 30, 2027 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| July 29, 2026 Filed Jul 30, 2026 20:01 UTC | COMPUGEN LTD CGEN · Entity 6149 | GrantOrdinary Shares | 13,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-003706 · zk2635765.xml · nonDerivative · entry 1 Mahler Michelle · CIK 0002041318 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,625 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.